linjc16/ctgov huggingface dataset:
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.

Official Title
-----------------
A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC)

Conditions
-----------------
Carcinoma, Renal Cell, Metastases, Neoplasm

Intervention / Treatment
-----------------
* Drug: GTI-2040


Participation Criteria
=================
Eligibility Criteria
-----------------
Age greater than or equal to 18. Histologically or cytologically confirmed diagnosis of advanced or metastatic renal cell carcinoma for which no effective therapy is available or that is unresponsive to conventional therapy. Measurable disease. To be considered measurable, a lesion must be accurately measured in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral CT scan. Karnofsky performance status of greater than or equal to 70. Be able to have a central venous like access maintained throughout the study. Provide written informed consent prior to the initiation of protocol therapy. Appropriate organ function.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: GTI-2040|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Metastatic Renal Cell Carcinoma
Observatory of Screening Aneurysms of the Abdominal Aorta During Echocardiography. National Epidemiological Survey

Study Overview
=================
Brief Summary
-----------------
Study of the prevalence of Abdominal Aortic Aneurysms (AAA) (> 3 cm) in patients with echocardiography (transthoracic or) during a specific day, with cardiologists in France. This is a cross-sectional epidemiological investigation, assembling evidence from a routine ultrasound screening for AAA at the waning of echocardiograms performed during a specific day. The study will be offered a list of centers selected by the Scientific Committee in the complete list of locations being in France, the subsidiary of echocardiography Echocardiography of French Society of Cardiology. These centers will be 500 in number representative of the French centers, geographically and by type of centers.

Detailed Description
-----------------
Multicenter observational study collecting data from a routine ultrasound screening for AAA at the waning of echocardiograms performed during a specific day. All of the cardiologists practicing echocardiography are invited to participate in this study, each cardiologist should include echocardiography in 10 patients examined for any reason and will be considered referring cardiologist. There will be no follow-up, the idea is to have a database with measures of abdominal aortic aneurysms and therefore.

Official Title
-----------------
Observatory of Screening Aneurysms of the Abdominal Aorta During Echocardiography. National Epidemiological Survey

Conditions
-----------------
Abdominal Aortic Aneurysms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient > 65 years, Have an echocardiogram, whatever the reason, Having agreed to participate in the study. Exclusion Criteria: Patients already operated in the aorta (AAA, PAD, stent, ...) Patient refusal to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Echocardiography<br>patients with echocardiography | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of patients with AAA among those with echocardiography. | Discovery of the aneurysm of the abdominal aorta at the waning of echocardiography | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transthoracic echocardiography
Pain Control In First Trimester Medical Abortion: A Randomized Trial

Study Overview
=================
Brief Summary
-----------------
This trial will compare two oral analgesic regimens in women undergoing first trimester medical abortion with mifepristone and misoprostol. The primary study outcome is pain.

Detailed Description
-----------------
This trial will compare two oral analgesic regimens in women undergoing first trimester medical abortion with mifepristone and misoprostol. The primary study outcome is pain. Secondary objectives include comparing the regimens for the total amount of ibuprofen taken, use of other analgesics, vaginal bleeding, adverse events, successful completion of abortion, overall satisfaction with the abortion procedure.

Official Title
-----------------
PAIN CONTROL IN FIRST TRIMESTER MEDICAL ABORTION: A Randomized Trial

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: Ibuprofen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women with a gestational age of 63 days or less Desire a medical abortion with mifepristone and misoprostol Exclusion Criteria: - Have contraindications to ibuprofen
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Therapeutic<br>Ibuprofen | Drug: Ibuprofen<br>* Ibuprofen<br>|
| Active Comparator: Prophylactic<br>Ibuprofen | Drug: Ibuprofen<br>* Ibuprofen<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 11-point Visual Analog Scale for Pain | Participant pain was assessed using an 11-point Visual Analog Scale for Pain. Scores ranged from 0 (no pain) to 10 (worst pain possible) | 1-2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain, medical abortion
RHEology of the Pulmonary MUcus

Study Overview
=================
Brief Summary
-----------------
Patients for whom bronchial mucus collection has been performed as part of the treatment will be offered the opportunity to participate in the study. A rheology measurement will be carried out shortly after the collection of fresh bronchial mucus samples. Another part will be done on frozen bronchial mucus samples

Official Title
-----------------
Protocol for the Collection of Lung Mucus Samples From Care for a Rheology Research Programme

Conditions
-----------------
Bronchial Mucus in COPD and Cystic Fibrosis

Intervention / Treatment
-----------------
* Biological: bronchial mucus collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female over 18 years of age. Patient consulting or hospitalised in the pneumology department and for whom an emission of bronchial mucus is planned as part of the treatment (mucus from respiratory physiotherapy sessions for patients with cystic fibrosis or COPD, bronchial aspirations from the bronchial fibroscopy programme). Exclusion Criteria: Patient being opposed to the use of his mucus samples and data for this research. Patient protected by law (guardianship or curatorship), subject deprived of liberty

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: bronchial mucus collection|mucus resulting from respiratory physiotherapy sessions for patients with cystic fibrosis or COPD, bronchial aspirations resulting from the bronchial fibroscopy programme|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reproducibility of the rheology parameters studied | Establish operating protocols for obtaining reliable rheological measurements with a view to using them as biomarkers | Day 1 |
Serial Therapeutic and Antifungal Monitoring Protocol

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to investigate T2Candida performance as a monitoring tool for post-therapy clearance of Candida compared to blood culture. This study will collect a T2clinical specimen and companion blood culture from patients who have exhibited a positive blood culture by gram stain for yeast, and who are receiving treatment with antifungal therapy.

Detailed Description
-----------------
One blood culture and one set of T2clinical specimens will be collected at specified intervals to monitor the clearance of Candida infection from the bloodstream. Each T2 result will be compared to the companion blood culture result. The comparison will determine if the presence of antifungal therapy inhibits blood culture and leads to an incidence of blood culture false negative test results. The T2 result, which is not impacted by the presence of antifungal therapy, can show that the pathogen is still present for some additional period of time.

Official Title
-----------------
Serial Therapeutic and Antifungal Monitoring Protocol

Conditions
-----------------
Candidemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject or subject's authorized representative must be able to understand, read and sign the study specific informed consent form after the nature of the study has been fully explained to them. Subject is between 18-95 years of age Subject has a blood culture result that is positive for yeast within 36 hours of enrollment Exclusion Criteria: Subject has other co-morbid condition(s) that, in the opinion of the Investigator, could limit the subject's ability to participate in the study or impact the scientific integrity of the study All T2 Bio individual clinical research specimens contain < 3 ml of blood Use of any novel (i.e. not commercially available) drug compound within 30 days prior to the collection of T2 Bio blood specimens.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Candida Positive Patients<br>Symptomatic adult patients, confirmed via blood culture with species identification to be positive for Candida | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to negative test result | The number of days to a negative test result will be compared between the T2Candida Test and blood culture. | 14 days post enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Candida, Blood culture, Antifungal therapy, Sepsis
Dietary Antioxidants and Atherosclerosis

Study Overview
=================
Brief Summary
-----------------
To examine the role of dietary antioxidants in the etiology of atherosclerosis in both sexes and in whites and Blacks.

Detailed Description
-----------------
BACKGROUND: Atherosclerosis is this nation's leading cause of death for males and females, and Blacks and whites. There is mounting evidence that the oxidation of blood low density lipoproteins (LDL) plays an important role in the pathogenesis of this disease. LDL oxidation can be prevented by several dietary antioxidants, in particular, vitamin C, vitamin E, and beta-carotene. There is preliminary evidence that dietary antioxidants may slow the natural history of atherosclerosis in humans. Until now studies in this area have included predominantly white males with symptomatic disease. DESIGN NARRATIVE: The case-control study used data collected in ARIC to test the hypothesis that individuals in the lowest quintile of vitamin C, vitamin E and carotenoid consumption were at higher risk of asymptomatic atherosclerosis than those consuming greater amounts. Antioxidant intake was assessed by a validated food frequency questionnaire and a diet supplement survey. Cases were those with asymptomatic carotid artery atherosclerosis as determined by B-mode ultrasonography. Controls were those without evidence of carotid artery atherosclerosis. Secondary analyses determined which sex-race subgroups were at particular risk due to low antioxidant consumption. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Carotid Stenosis

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
[C-11]NOP-1A and Alcohol Use Disorder

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to compare [C-11]NOP-1A binding in recently abstinent alcohol use disorders and controls

Detailed Description
-----------------
This will allow for understanding brain stress and antistress mechanisms that underlie abuse of alcohol in humans

Official Title
-----------------
Linking Nociceptive Opioid Peptide (NOP) Receptors With Relapse in Alcoholism

Conditions
-----------------
Alcohol Use Disorder

Intervention / Treatment
-----------------
* Radiation: [C-11]
* Drug: NOP-1A


Participation Criteria
=================
Eligibility Criteria
-----------------
[A] Alcohol use disorders (AUD) Inclusion Criteria: Males or Females Fulfill DSM5 diagnosis for alcohol use disorder Medically Healthy Exclusion Criteria: Pregnancy or lactation Comorbid severe/major medical, psychiatric (such as bipolar and psychotic disorders, etc.,) and current comorbid drug use disorders (other than tobacco use and recreational marijuana use) Metal implants or paramagnetic objects contained within the body which may interfere with MRI scans Currently employed as a radiation worker, or participation in radiation drug research procedures within the previous year Currently on any psychotropic medications that can influence nociceptin transmission in the brain [B]Healthy controls Inclusion Criteria: Males or females Absence of present or past psychiatric conditions (including alcohol or drug use disorders) Medically Healthy Exclusion Criteria: Pregnancy of lactation Medical, psychiatric or comorbid drug/alcohol use disorders Metal implants or paramagnetic objects contained within the body which may interfere with the MRI scan Currently employed as a radiation worker; or participation in radioactive drug research protocols within the previous year Currently on any psychotropic medications that can influence nociceptin transmission in the brain Family history of psychotic disorder, manic episode, drug and alcohol use disorder in first-degree relatives

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: [C-11]NOP-1A
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Alcohol use disorders<br>[C-11]NOP-1A PET Scan | Radiation: [C-11]<br>* Radiolabel<br>Drug: NOP-1A<br>* Tracer<br>|
| Experimental: Controls<br>[C-11]NOP-1A PET Scan | Radiation: [C-11]<br>* Radiolabel<br>Drug: NOP-1A<br>* Tracer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| [C-11]NOP-1A VT | VT-Volume of distribution expressed relative to total plasma | Baseline |
Safety of Tranexamic Acid in Reducing Blood Loss Myomectomy.

Study Overview
=================
Brief Summary
-----------------
Uterine leiomyomas (fibroids) are the most common benign tumors among women . Fibroids are found in approximately 15% to 30% of women in the reproductive age group

Detailed Description
-----------------
Although most of them are asymptomatic, 20-50% of fibroids may cause problems such as heavy menstrual bleeding, anemia, pelvic pain, pressure symptoms from extrinsic compression of the colorectal and urinary tract, infertility, and recurrent pregnancy losses, where surgical intervention is often indicated

Official Title
-----------------
Safety of Tranexamic Acid Versus Misoprostol in Reducing Blood Loss in Myomectomy.

Conditions
-----------------
Myoma

Intervention / Treatment
-----------------
* Drug: women receiving tranexamic acid
* Drug: women receiving misoprostol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women with myomas Exclusion Criteria: with with malignant lesions

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: women receiving tranexamic acid<br> | Drug: women receiving tranexamic acid<br>* women receiving tranexamic acid during myomectomy<br>|
| Active Comparator: women receiving misoprostol<br> | Drug: women receiving misoprostol<br>* women receiving misoprostol in myomectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the number of women who will have less blood loss | how many women will have less blood loss | 48 hours |
Study of Health Personnel and the Assistance to Patients With Tuberculosis in Hospital Environment

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate in hospital environment the knowledge of the health care professionals about fundamental concepts on tuberculosis and the accomplishment to respiratory isolation practices for patients with pulmonary tuberculosis hospitalized in a public hospital in Fortaleza, Ceará, Brazil.

Detailed Description
-----------------
A cross-sectional study of health care professionals using a study instrument with questions to evaluate the knowledge of basic concepts about tuberculosis. A retrospective study reviewing medical records of patients with suspected tuberculosis hospitalized in the units of Adult and Pediatric Clinics and in the Critical Care Unit in a general hospital in Fortaleza-CE.

Official Title
-----------------
Health Personnel and the Control of Tuberculosis in a Hospital Environment

Conditions
-----------------
Tuberculosis, Health Care Professionals, Hospital Environment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Health care professionals working in a public hospital (HGWA) in the units of Adult and Pediatric Clinics and in the Critical Care Unit in a general hospital in Fortaleza-CE Exclusion Criteria: Health care professionals working in HGWA but in units other than Adult and Pediatric Clinics and in the Critical Care Unit
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tuberculosis, Disease transmission, Exposure to biological agents, Health personnel